Posted 24th May 2019 by Joshua Broomfield
The European Medicines Agency published a “Reflection paper on chronic liver diseases (PBC, PSC, and NASH)” in Autumn 2018. Elmer Schabel gives a detailed display of the contents of this first regulatory guidance with regard to NASH, as well as a preliminary evaluation of the initial feedback and input received by stakeholders.
Posted 22nd May 2019 by Joshua Broomfield
In my previous post, I discussed the likely applications of Blockchain technology in the short, medium, and long-term future. These applications follow on from the key strategic priorities necessitated by the healthcare industry’s trend towards digital decentralized care delivery models.
Posted 20th May 2019 by Joshua Broomfield
We are building the solutions that will revolutionise healthcare in the future: solutions that will transform the trust relationship between the industry and patients, and the whole dynamic of healthcare. As co-founder of 23 Consulting, I am involved in supporting health organisations with their blockchain projects.
Posted 17th May 2019 by Joshua Broomfield
Radiology is ahead of the curve because they’ve had CAD (Computer Aided Detection) for about 20 years. Radiology as a field has therefore had experience of introducing and integrating AI algorithms.
In my previous post, I talked about high-level cross imaging modalities. Here, I will discuss three challenges specific to pathology. I also work with Radiology imaging, and I think that comparisons between the two can help see how pathology might develop in the future.
Posted 15th May 2019 by Joshua Broomfield
The first topic I worked on that combined Blockchain and healthcare was the project I’m going to talk about at the Blockchain in Healthcare Congress. It was commissioned by the Finnish government, looking at how blockchain technology and Smart Contracts could help in a planned governmental social and healthcare reform.
Posted 13th May 2019 by Joshua Broomfield
NOX enzymes are a family of enzymes which amplify multiple signaling pathways associated with liver disease. At the Global NASH Congress, Alexandre Grassin shared a presentation about Genkyotex’s novel molecule GTK831, a NOX1/4 inhibitor, and the interim results from its phase two trial.
Posted 10th May 2019 by Joshua Broomfield
Unsurprisingly, there is a lot of hype surrounding AI. Available deep learning packages make it so easy to create models and so we can expect lots of them to emerge. Anyone able to access sufficiently labelled data can start building models.
Posted 8th May 2019 by Joshua Broomfield
Microbiome research is abundant and profoundly inspiring. Whether focusing on cancer drug response, or the more classical field of gut discomfort solutions, we are clearly on the brink of some long-anticipated breakthroughs. But despite the promise, companies in the field face challenges.